Oral News and Research

RSS

Court's rejection of fast-track request raises questions, issues

The court's online order did not offer any legal reasoning, nor were dissenting opinions noted. However, Justice Elena Kagan did participate in the decision. Meanwhile, Politico Pro explores some of the key questions that will be at stake surrounding the law's "individual mandate" as the challenges now wind through through the federal appeals courts this summer.

27 Apr 2011

Boehringer Ingelheim initiates enrollment in BI 201335 Phase 3 clinical trial for chronic HCV

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that enrollment has commenced at North American sites in its pivotal Phase 3 clinical trial program for BI 201335, the Company's investigational, oral protease inhibitor for the treatment of chronic hepatitis C virus (HCV).

27 Apr 2011

Researchers develop protein-based inhibitor that can treat HPV

Human papillomavirus causes cervical cancer, the second most common cause of cancer death for women, and is a common cause of anogenital and some head and neck cancers.

27 Apr 2011

Diabetes and prediabetes are on the rise: New medication in research trials

As the newest statistics from the CDC show, diabetes is an ever increasing problem for Americans. Almost 26 million adults in this country now have diabetes, an increase of 9% since 2008. Ninety to 95% of cases are type 2 diabetes, marked by a gradual inability of the body’s cells to respond to insulin, and eventually an inability to produce enough insulin. In addition, almost 79 million people in this country have prediabetes. The CDC has warned that if diabetes continues on its current course, it could affect a third of all adult Americans by 2050.

26 Apr 2011

Newer birth control pill raises risk of blood clots

Two human trials in the US and the UK including women from both populations showed that women taking newer forms of oral contraceptives, which include drosperinone, a synthetic version of the hormone progesterone, increased their risk of developing a blood clots by two or three times over those taking older birth control pills that rely on a different form of the hormone known as levonorgestrel.

26 Apr 2011

Experts to present research on vascular biology and disease at ATVB meetings

Nearly 1,200 experts in cardiovascular medicine, vascular biology, endocrinology, hematology and other disciplines are expected to attend the American Heart Association's Arteriosclerosis, Thrombosis and Vascular Biology 2011 Scientific Sessions, April 28-30, in Chicago, Ill.

26 Apr 2011

KemPharm to formulate and develop KP106 as oral film dosage for ADHD treatment

KemPharm, Inc. today announced that KP106, its clinical candidate for Attention Deficit/Hyperactivity Disorder, will be formulated and developed in an oral film dosage form pursuant to an exclusive collaboration agreement with MonoSol Rx relating to the development, commercialization and manufacture of KP106.

26 Apr 2011

BMY to present belatacept Phase III new data at American Transplant Congress

New data on belatacept, an investigational selective T cell costimulation blocker being studied for use in renal transplantation by Bristol-Myers Squibb Company, will be presented at the American Transplant Congress April 30 - May 4, 2011 in Philadelphia.

26 Apr 2011

Aussies avoiding regular dental check-ups: Report

According to a new report, the annual visit to the dentist is becoming a luxury for many Australians and almost 40 per cent of the population does not go for regular check-ups.

25 Apr 2011

MonoSol Rx, KemPharm enter development and commercialization partnership for ADHD prodrug

MonoSol Rx, LLC, the developer of PharmFilm® drug delivery technology, today announced that the Company has entered into a development and commercialization partnership with KemPharm, a biopharmaceutical company focused on the discovery and development of new, safer therapies for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), pain, and cardiovascular disease.

25 Apr 2011

Nausea and vomiting are most feared of all chemotherapy-related side effects

PediatRx, Inc. today commented on studies which reveal that chemotherapy-induced nausea and vomiting is one of the most feared of all chemotherapy-related side effects. The fear of nausea and subsequent vomiting is many times so significant that patients can develop a condition known as 'anticipatory' nausea, where the patient becomes nauseous primarily as a result of the fear of becoming nauseous.

25 Apr 2011

Pharmatek purchases spray dryer for drug formulation and manufacturing

Pharmatek Laboratories, Inc., a premier contract development and manufacturing organization supporting the pharmaceutical industry, announced that it has added spray drying to its drug formulation and manufacturing capabilities. The company has purchased a Buchi B-290 Mini Spray Dryer for formulation feasibility studies and small-scale clinical manufacture. This technology can be used for both oral and parenteral dosage forms.

25 Apr 2011

Bayer's oral contraceptives may increase risk of blood clots, stroke or heart attack

Bayer HealthCare Pharmaceuticals, Inc. is aware of two studies published today in The British Medical Journal, ONLINE FIRST.

25 Apr 2011

Pharmasset reports net loss of $19.9 million for quarter ended March 31, 2011

Pharmasset, Inc., a clinical stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections, today reported financial results and operational highlights for the quarter ended March 31, 2011.

25 Apr 2011

Burchfield Primary School third-grader to receive $1,000 PDA's poster contest prize

Bailey Ritchey, a third-grade student at Burchfield Primary School in Allegheny County, will receive a $1,000 educational bond for winning first-place in the Pennsylvania Dental Association's 2011 National Children's Dental Health Month statewide poster contest.

25 Apr 2011

Pfizer comments on abstract concerning ORAL Sync tofacitinib Phase 3 study in RA

Pfizer Inc. commented on an abstract concerning the ORAL Sync Phase 3 study of tofacitinib in patients with rheumatoid arthritis which has been posted for the European League Against Rheumatism conference.

25 Apr 2011

Two studies about oral health inequalities in older people published in IADR/AADR journal

The International and American Associations for Dental Research (IADR/AADR) have published two studies about oral health inequalities in older people and low income individuals.

25 Apr 2011

Bayer's birth control pills may increase risk of venous thromboembolism

The following release is being issued by law firms RodaNast, P.C.; Levin, Fishbein, Sedran & Berman and Feldman & Pinto: According to two new studies published in the online edition of the British Medical Journal, Bayer's birth control pills Yaz and Yasmin, containing a new progestin drospirenone, carry up to triple the risk of serious blood clots over traditional pills containing the progestin levonorgestrel.

25 Apr 2011

Daiichi Sankyo's LIXIANA receives Japanese marketing approval

Daiichi Sankyo Company, Limited, announced today that the company has received its first marketing approval for LIXIANA 15 mg and 30 mg tablets, by the Ministry of Health, Labor and Welfare in Japan.

22 Apr 2011

Teva acknowledges promising results of DEFINE study in MS

We acknowledge the results of the DEFINE study seem promising for patients. It is important to note that as a general rule, results obtained in clinical trials in multiple sclerosis (MS) cannot be compared, unless agents are tested in a head-to-head manner in the same trial.

22 Apr 2011